"The U.S. Food and Drug Administration today approved Vimizim (elosulfase alfa), the first FDA-approved treatment for Mucopolysaccharidosis Type IVA (Morquio A syndrome). Morquio A syndrome is a rare, autosomal recessive lysosomal storage disease "...
(Generic versions may still be available.)
Although signs and symptoms of ergotism rarely develop even after long term intermittent use of the orally administered drug, care should be exercised to remain within the limits of recommended dosage.
Nursing Mothers. It is not known whether the ergotamine tartrate in Wigraine (ergotamine and caffeine) ® is excreted in human milk. Because some ergot alkaloids have been found in the milk of nursing mothers resulting in symptoms of ergotism in their children, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.
Pediatric Usage. Safety and effectiveness in children have not been established.
Last reviewed on RxList: 12/8/2004
This monograph has been modified to include the generic and brand name in many instances.
Additional Wigraine Information
Wigraine - User Reviews
Wigraine User Reviews
Now you can gain knowledge and insight about a drug treatment with Patient Discussions.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find the secrets to longer life.